FY2027 EPS Estimates for Kura Oncology Cut by HC Wainwright

Kura Oncology, Inc. (NASDAQ:KURA) – Equities research analysts at HC Wainwright decreased their FY2027 earnings estimates for shares of Kura Oncology in a research note issued on Friday, June 12th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($2.82) per share for the year, down from their prior estimate of ($2.70). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.47) per share. HC Wainwright also issued estimates for Kura Oncology’s FY2028 earnings at ($2.44) EPS and FY2029 earnings at ($2.25) EPS.

Other equities research analysts have also recently issued reports about the stock. Sanford C. Bernstein set a $24.00 price objective on shares of Kura Oncology in a research note on Monday. Jefferies Financial Group set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, May 28th. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research note on Thursday, May 28th. Zacks Research raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Thursday, February 26th. Finally, UBS Group reissued a “buy” rating and issued a $15.00 price objective (down from $16.00) on shares of Kura Oncology in a research note on Friday, March 13th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $25.46.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $9.54 on Tuesday. The stock has a market cap of $846.87 million, a price-to-earnings ratio of -2.85 and a beta of 0.36. Kura Oncology has a 52 week low of $5.45 and a 52 week high of $12.49. The company’s 50-day moving average price is $9.33 and its 200 day moving average price is $9.29. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. The firm had revenue of $18.27 million for the quarter, compared to analysts’ expectations of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently modified their holdings of KURA. IFP Advisors Inc lifted its stake in shares of Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after buying an additional 1,284 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Kura Oncology by 392.8% during the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after buying an additional 3,072 shares during the period. Allworth Financial LP lifted its stake in shares of Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after buying an additional 1,553 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Kura Oncology by 127.2% during the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after buying an additional 3,769 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after buying an additional 9,958 shares during the period.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.